Theravance Biopharma, Inc.
TBPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $64 | $57 | $51 | $55 |
| % Growth | 12.1% | 11.8% | -7.2% | – |
| Cost of Goods Sold | $0 | $41 | $63 | $194 |
| Gross Profit | $64 | $17 | -$12 | -$138 |
| % Margin | 100% | 29.3% | -23.5% | -250.1% |
| R&D Expenses | $38 | $46 | $70 | $202 |
| G&A Expenses | $65 | $65 | $59 | $0 |
| SG&A Expenses | $69 | $70 | $67 | $0 |
| Sales & Mktg Exp. | $4 | $5 | $8 | $0 |
| Other Operating Expenses | $5 | -$44 | -$57 | -$82 |
| Operating Expenses | $111 | $73 | $80 | $119 |
| Operating Income | -$47 | -$56 | -$92 | -$258 |
| % Margin | -72.9% | -97.6% | -179.1% | -466.1% |
| Other Income/Exp. Net | $2 | $7 | -$1 | -$7 |
| Pre-Tax Income | -$45 | -$49 | -$93 | -$265 |
| Tax Expense | $12 | $6 | $0 | -$0 |
| Net Income | -$56 | -$55 | $872 | -$199 |
| % Margin | -87.6% | -96.1% | 1,698.5% | -360.6% |
| EPS | -1.15 | -1 | -1.26 | -2.87 |
| % Growth | -15% | 20.6% | 56.1% | – |
| EPS Diluted | -1.15 | -1 | -1.26 | -2.87 |
| Weighted Avg Shares Out | 49 | 55 | 74 | 69 |
| Weighted Avg Shares Out Dil | 49 | 55 | 74 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $9 | $9 | $1 |
| Interest Expense | $3 | $2 | $6 | $9 |
| Depreciation & Amortization | $4 | $2 | $3 | $5 |
| EBITDA | -$38 | -$52 | -$76 | -$233 |
| % Margin | -59.7% | -89.9% | -148.2% | -420.9% |